2014年10月14日,辉瑞公司研制的B型脑膜炎球菌疫苗Trumenba获得美国食品药品管理局(FDA)批准。该疫苗适用于10~25岁的人群。在美国、欧洲和澳大利亚共4 500人的临床试验中,Trumenba取得了良好的效果,因此提前获得美国FDA的批准。Trumenba是第1个美国批准的用于预防由B型脑膜炎球菌引起侵袭性感染的疫苗。辉瑞公司的统计数据显示,在 On October 14, 2014, Pfizer’s Trumanba meningococcal meconium-type B vaccine was approved by the U.S. Food and Drug Administration (FDA). The vaccine is suitable for 10 to 25-year-olds. Trumenba has achieved good results in a total of 4,500 clinical trials in the United States, Europe and Australia and has received FDA approval in advance. Trumenba is the first vaccine approved by the United States for the prevention of invasive infections caused by meningococcal disease. Pfizer’s statistics show that at